
    
      Patients with clinically significant PoPH (resting mean pulmonary arterial pressure >25 mm
      Hg, pulmonary vascular resistance >400 dynes*s*cm-5) will be offered treatment with
      ambrisentan. Patients will be followed clinically and hemodynamically up to 12 months after
      start of treatment.
    
  